|
AstraZeneca PLC on Monday said a test of its baxdrostat drug showed a ‘meaningful reduction’ in hypertension. The Cambridge, England-based pharmaceutical and biotechnology firm reported that some primary endpoints and all secondary endpoints were met in a third-phase trial of baxdrostat. Testing measured systolic blood pressure, or SBP, in patients with ‘uncontrolled or treatment resistant hypertension’, who were administered one of two different baxdrostat doses, or a placebo. AstraZeneca said the drug showed a ‘statistically significant’ reduction in mean seated SBP. AstraZeneca shares were up 2.2% to 10,681.21 pence in London after the Monday morning announcement. Baxdrostat is a selective inhibitor of aldosterone, the hormone that may be responsible for higher SBP, according to some researchers. The drug is under investigation for potential use as a monotherapy for hypertension, and as a possible kidney disease treatment in combination with dapagliflozin. AstraZeneca also hopes the drug will help prevent heart failure, given that high SBP is a ‘leading risk factor for cardiovascular disease’, noted the trial’s primary investigator, Bryan Williams. Commented Sharon Barr, AstraZenca’s executive vice president of Biopharmaceuticals Research & Development: ‘These findings provide compelling evidence of baxdrostat’s potential to address a critical unmet need by targeting aldosterone dysregulation, bringing a novel mechanism to a field that has seen little innovation in over two decades.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
